These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 33855897)
1. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. Signoriello E; Lus G; Bonavita S; Lanzillo R; Saccà F; Landi D; Frau J; Baroncini D; Zaffaroni M; Maniscalco GT; Curti E; Sartori A; Cepparulo S; Marfia GA; Nicoletti CG; Carotenuto A; Nociti V; Caleri F; Sormani MP; Signori A Mult Scler; 2022 Jan; 28(1):93-101. PubMed ID: 33855897 [TBL] [Abstract][Full Text] [Related]
2. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry. Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T; J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958 [TBL] [Abstract][Full Text] [Related]
3. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186 [TBL] [Abstract][Full Text] [Related]
10. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Zhu C; Zhou Z; Roos I; Merlo D; Kalincik T; Ozakbas S; Skibina O; Kuhle J; Hodgkinson S; Boz C; Alroughani R; Lechner-Scott J; Barnett M; Izquierdo G; Prat A; Horakova D; Kubala Havrdova E; Macdonell R; Patti F; Khoury SJ; Slee M; Karabudak R; Onofrj M; Van Pesch V; Prevost J; Monif M; Jokubaitis V; van der Walt A; Butzkueven H; J Neurol Neurosurg Psychiatry; 2022 Dec; 93(12):1330-1337. PubMed ID: 36261289 [TBL] [Abstract][Full Text] [Related]
11. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients. Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643 [TBL] [Abstract][Full Text] [Related]
13. Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception. Demortiere S; Maarouf A; Rico A; Boutiere C; Hilezian F; Durozard P; Pelletier J; Audoin B Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37550074 [TBL] [Abstract][Full Text] [Related]
14. Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria. Guger M; Enzinger C; Leutmezer F; Di Pauli F; Kraus J; Kalcher S; Kvas E; Berger T; J Neurol; 2023 Jun; 270(6):3103-3111. PubMed ID: 36862148 [TBL] [Abstract][Full Text] [Related]
15. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. Ferraro D; Iaffaldano P; Guerra T; Inglese M; Capobianco M; Brescia Morra V; Zaffaroni M; Mirabella M; Lus G; Patti F; Cavalla P; Cellerino M; Malucchi S; Pisano E; Vitetta F; Paolicelli D; Sola P; Trojano M; J Neurol; 2022 Mar; 269(3):1463-1469. PubMed ID: 34292396 [TBL] [Abstract][Full Text] [Related]
16. Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Zhong M; van der Walt A; Stankovich J; Kalincik T; Buzzard K; Skibina O; Boz C; Hodgkinson S; Slee M; Lechner-Scott J; Macdonell R; Prevost J; Kuhle J; Laureys G; Van Hijfte L; Alroughani R; Kermode AG; Butler E; Barnett M; Eichau S; van Pesch V; Grammond P; McCombe P; Karabudak R; Duquette P; Girard M; Taylor B; Yeh W; Monif M; Gresle M; Butzkueven H; Jokubaitis VG Mult Scler; 2022 May; 28(6):958-969. PubMed ID: 34623947 [TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. Lorefice L; Mellino P; Frau J; Coghe G; Fenu G; Cocco E Neurol Sci; 2024 Aug; 45(8):3951-3959. PubMed ID: 38472551 [TBL] [Abstract][Full Text] [Related]
18. Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data. Rowles WM; Hsu WY; McPolin K; Li A; Merrill S; Guo CY; Green AJ; Gelfand JM; Bove RM Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35581005 [TBL] [Abstract][Full Text] [Related]
19. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies. Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946 [TBL] [Abstract][Full Text] [Related]